摘要目的 研究非小细胞肺癌(NSCLC)患者血清Ras相关区域家族1A(RASSF1A)基因启动子区域的甲基化状态及其临床意义.方法 采用甲基化特异性聚合酶链反应(MSP)技术,检测75例NSCLC患者血清RASSF1A基因启动子区域的甲基化状态,并分析其与临床病理参数之间的相关性.结果75例NSCLC患者血清RASSF1A基因启动子区域异常甲基化检出率为30.7%(23/75),而35例肺部良性疾病患者和15例健康志愿者中检出率均为0,差异有统计学意义(P＜0.001).RASSF1A启动子异常甲基化与NSCLC患者的年龄、性别、病理类型无显著相关性,但在晚期及肿瘤分化程度较低的患者中检出率较高(P＜0.05).结论 RASSF1A启动子异常甲基化在NSCLC的发生、发展中起重要作用,有望成为NSCLC辅助诊断和预后判断的分子标记.

abstractsObjective To detect the hypermethylation status of RASSF1 A promoter in selMm DNA of non-small cell lung cancer(NSCLC)patient and evaluate its correlation with clinicopathological parameters.Methods Serum DNA was extracted from the peripheral blood of 75 NSCLC patients and another 35 patients with benign pulmonary disease and 15 healthy donors.The methylation status of RASSF1 A promoter was determined using mthylation-specific PCR(MSP),and the correlation of methylation profiles with clinicopathological parameters was statistically analyzed. Results Aberrant methylation of RASSF1 A was detected in 23 of 75(30.7%)cancer patients.but in none of patients with benign pulmonary disease or in healthy donors(P＜0.001).RASSF1 A hypermethylation status Was found to be correlated with late stage and poor differentiation(P＜0.05),but not with gender,age or histopathology in NSCLC patients.Conclusion Hypermethylated RASSF1 A promoter is frequently found in the serum DNA of non-small cell lung cancer patient,and RASSF1 A may become a promising novel biomarker for diagnosis and prognosis prediction in lung cancer.